Purchase this article with an account.
Lynne S. Gearinger, Kirk M. Bateman, Christine K. Hesje, Christine M. Sanfilippo, Timothy W. Morris; Comparative In Vitro Activity of Ophthalmic Antibacterials Against Ocular Pathogens From a 2009 - 2010 Bacterial Conjunctivitis Clinical Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1462.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess current trends among bacterial conjunctivitis (BC) pathogens, antimicrobial susceptibilities of besifloxacin and ophthalmic comparators were evaluated against all ocular pathogens recovered at or above threshold at baseline (Visit 1) in a 2009 - 2010 clinical study of besifloxacin ophthalmic suspension.
Antimicrobial susceptibility testing was conducted on all isolates identified as ocular pathogens against besifloxacin (BES) and comparator agents including moxifloxacin (MXF), gatifloxacin (GAT), and azithromycin (AZI). Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method following Clinical and Laboratory Standards Institute guidelines.
At baseline (Visit 1), a total of 27 species and 5 taxonomic groups of ocular pathogens were isolated from 202 randomized patients. Overall, 178 isolates comprising 58.4% Gram-positive and 41.6% Gram-negative organisms were recovered. Methicillin resistance (MR) was observed in 33.3% of S. aureus and S. epidermidis isolates combined. MIC50 and MIC90 values of besifloxacin and ophthalmic comparators against pathogens recovered from ≥ 10 infections are listed in the table below.
The distribution of pathogens recovered in this study was consistent with previous BC clinical trials. Furthermore, the relative potencies of besifloxacin and the three other most recently approved ophthalmic antibacterial agents were similar to previous clinical studies, particularly among methicillin-resistant staphylococci.
This PDF is available to Subscribers Only